

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on November 7, 2005.

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

AMENDMENT UNDER 37 CFR  
§1.825(a) THROUGH (c)  
Patent Application  
Docket No. C&R-102  
Serial No. 10/537,142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)  
Art Unit : (Not yet assigned)  
Applicants : Richard Joseph Fagan, Christopher Benjamin Phelps,  
Tania Maria Rodrigues, Melanie Yorke, Mariastella De Tiani  
Serial No. : 10/537,142  
Filed : June 2, 2005  
Confirm. No. : 1704  
For : Splice Variant of the Human Pituitary Growth Hormone

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 C.F.R. §§1.821-1.825: